$6.23 Billion is the total value of RA Capital Management's 92 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 36.6% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ASND | Buy | ASCENDIS PHARMA A/Ssponsored adr | $895,374,000 | +8.3% | 6,806,341 | +6.1% | 14.37% | +15.3% |
NVAX | Sell | NOVAVAX INC | $543,496,000 | -0.1% | 2,559,918 | -14.7% | 8.72% | +6.3% |
FMTX | FORMA THERAPEUTICS HLDGS INC | $224,300,000 | -11.2% | 9,011,651 | 0.0% | 3.60% | -5.4% | |
JANX | New | JANUX THERAPEUTICS INC | $216,333,000 | – | 8,670,644 | +100.0% | 3.47% | – |
VOR | VOR BIOPHARMA INC | $207,406,000 | -56.7% | 11,120,973 | 0.0% | 3.33% | -53.9% | |
AVTE | New | AEROVATE THERAPEUTICS INC | $188,667,000 | – | 8,263,982 | +100.0% | 3.03% | – |
NKTX | NKARTA INC | $177,627,000 | -3.7% | 5,605,129 | 0.0% | 2.85% | +2.5% | |
MGNX | Buy | MACROGENICS INC | $159,645,000 | +1.6% | 5,943,594 | +20.5% | 2.56% | +8.1% |
CNTB | Buy | CONNECT BIOPHARMA HLDGS LTDads | $136,534,000 | +146.7% | 6,991,003 | +133.7% | 2.19% | +162.7% |
TGTX | Sell | TG THERAPEUTICS INC | $129,665,000 | -42.0% | 3,342,743 | -27.9% | 2.08% | -38.2% |
IMGN | IMMUNOGEN INC | $121,371,000 | -18.6% | 18,417,458 | 0.0% | 1.95% | -13.4% | |
AVIR | ATEA PHARMACEUTICALS INC | $115,314,000 | -65.2% | 5,368,451 | 0.0% | 1.85% | -63.0% | |
ITOS | Buy | ITEOS THERAPEUTICS INC | $113,303,000 | -25.0% | 4,417,259 | +0.0% | 1.82% | -20.1% |
DAWN | New | DAY ONE BIOPHARMACEUTICALS I | $113,066,000 | – | 4,965,588 | +100.0% | 1.82% | – |
AXSM | AXSOME THERAPEUTICS INC | $111,676,000 | +19.1% | 1,655,447 | 0.0% | 1.79% | +26.8% | |
PHAT | PHATHOM PHARMACEUTICALS INC | $105,443,000 | -9.9% | 3,115,008 | 0.0% | 1.69% | -4.1% | |
TIL | INSTIL BIO INC | $94,104,000 | -23.0% | 4,870,793 | 0.0% | 1.51% | -18.0% | |
RCKT | ROCKET PHARMACEUTICALS INC COM | $93,326,000 | -0.2% | 2,107,149 | 0.0% | 1.50% | +6.2% | |
ETNB | Buy | 89BIO INC | $92,860,000 | -17.2% | 4,965,769 | +4.8% | 1.49% | -11.9% |
ZGNX | ZOGENIX INC | $91,307,000 | -11.5% | 5,283,976 | 0.0% | 1.46% | -5.8% | |
PCVX | VAXCYTE INC | $87,019,000 | +14.0% | 3,865,808 | 0.0% | 1.40% | +21.4% | |
KNTE | KINNATE BIOPHARMA INC | $83,646,000 | -25.3% | 3,593,052 | 0.0% | 1.34% | -20.4% | |
GRPH | New | GRAPHITE BIO INC | $82,921,000 | – | 2,698,369 | +100.0% | 1.33% | – |
TVTX | TRAVERE THERAPEUTICS INC | $81,915,000 | -41.6% | 5,614,428 | 0.0% | 1.32% | -37.8% | |
HOWL | New | WEREWOLF THERAPEUTICS INC | $74,850,000 | – | 4,291,881 | +100.0% | 1.20% | – |
RYTM | RHYTHM PHARMACEUTICALS INC | $71,077,000 | -31.4% | 4,871,067 | 0.0% | 1.14% | -27.0% | |
CYT | New | CYTEIR THERAPEUTICS INC | $69,488,000 | – | 3,247,117 | +100.0% | 1.12% | – |
GHRS | New | GH RESEARCH PLCordinary shares | $64,733,000 | – | 2,978,955 | +100.0% | 1.04% | – |
OLMA | OLEMA PHARMACEUTICALS INC | $60,168,000 | -15.7% | 2,150,404 | 0.0% | 0.97% | -10.2% | |
DYN | DYNE THERAPEUTICS INC | $59,018,000 | +35.5% | 2,805,045 | 0.0% | 0.95% | +44.1% | |
PMVP | PMV PHARMACEUTICALS INC | $58,423,000 | +3.9% | 1,710,265 | 0.0% | 0.94% | +10.6% | |
KALA | KALA PHARMACEUTICALS INC | $57,635,000 | -21.4% | 10,874,613 | 0.0% | 0.92% | -16.3% | |
CRIS | CURIS INC | $57,621,000 | -28.7% | 7,140,091 | 0.0% | 0.92% | -24.1% | |
CERE | CEREVEL THERAPEUTICS HLDNG INC | $56,364,000 | +86.6% | 2,200,000 | 0.0% | 0.90% | +98.9% | |
EWTX | EDGEWISE THERAPEUTICS INC | $55,749,000 | -34.4% | 2,613,623 | 0.0% | 0.90% | -30.1% | |
ORTX | ORCHARD THERAPEUTICS PLCads | $54,064,000 | -21.8% | 12,315,213 | 0.0% | 0.87% | -16.8% | |
SBTX | SILVERBACK THERAPEUTICS INC | $53,816,000 | -29.2% | 1,742,186 | 0.0% | 0.86% | -24.6% | |
VERV | New | VERVE THERAPEUTICS INC | $53,037,000 | – | 880,284 | +100.0% | 0.85% | – |
CCCC | C4 THERAPEUTICS INC | $52,127,000 | +2.3% | 1,377,569 | 0.0% | 0.84% | +9.0% | |
WVE | WAVE LIFE SCIENCES LTD | $51,783,000 | +18.7% | 7,775,207 | 0.0% | 0.83% | +26.3% | |
TRILLIUM THERAPEUTICS INC | $51,318,000 | -9.7% | 5,290,481 | 0.0% | 0.82% | -3.9% | ||
ACHL | Buy | ACHILLES THERAPEUTICS PLCsponsored ads | $49,094,000 | +113.6% | 5,014,687 | +261.1% | 0.79% | +127.1% |
CCXI | Sell | CHEMOCENTRYX INC | $46,820,000 | -74.3% | 3,496,639 | -1.7% | 0.75% | -72.7% |
KALV | Buy | KALVISTA PHARMACEUTICALS INC | $46,251,000 | +414.4% | 1,930,322 | +451.5% | 0.74% | +445.6% |
ARDX | ARDELYX INC | $46,066,000 | +14.5% | 6,077,294 | 0.0% | 0.74% | +21.7% | |
SLDB | SOLID BIOSCIENCES INC | $45,266,000 | -33.8% | 12,367,873 | 0.0% | 0.73% | -29.5% | |
DSGN | DESIGN THERAPEUTICS INC | $43,492,000 | -33.5% | 2,186,636 | 0.0% | 0.70% | -29.2% | |
GERN | GERON CORP | $42,478,000 | -10.8% | 30,126,299 | 0.0% | 0.68% | -5.0% | |
STSA | SATSUMA PHARMACEUTICALS INC | $41,695,000 | +19.3% | 5,914,252 | 0.0% | 0.67% | +26.9% | |
LEGN | New | LEGEND BIOTECH CORPsponsored ads | $40,126,000 | – | 977,503 | +100.0% | 0.64% | – |
BOLT | BOLT BIOTHERAPEUTICS INC | $36,769,000 | -53.0% | 2,378,325 | 0.0% | 0.59% | -50.0% | |
INZY | INOZYME PHARMA INC | $34,142,000 | -13.9% | 2,003,653 | 0.0% | 0.55% | -8.4% | |
VRNA | VERONA PHARMA PLCsponsored ads | $33,354,000 | -21.8% | 5,100,000 | 0.0% | 0.54% | -16.8% | |
BDTX | BLACK DIAMOND THERAPEUTICS INC | $31,571,000 | -49.8% | 2,589,904 | 0.0% | 0.51% | -46.5% | |
AKUS | AKOUOS INC | $28,630,000 | -9.5% | 2,281,249 | 0.0% | 0.46% | -3.6% | |
CNTA | New | CENTESSA PHARMACEUTICALS PLCsponsored ads | $28,435,000 | – | 1,280,300 | +100.0% | 0.46% | – |
IPSC | New | CENTURY THERAPEUTICS INC | $26,820,000 | – | 914,094 | +100.0% | 0.43% | – |
NAUT | New | NAUTILUS BIOTECHNOLOGY INC | $24,961,000 | – | 2,471,430 | +100.0% | 0.40% | – |
CTMX | CYTOMX THERAPEUTICS INC | $22,155,000 | -18.1% | 3,500,000 | 0.0% | 0.36% | -12.7% | |
SCPH | SCPHARMACEUTICALS INC | $16,687,000 | -8.1% | 2,731,170 | 0.0% | 0.27% | -2.2% | |
LRMR | LARIMAR THERAPEUTICS INC | $14,879,000 | -32.8% | 1,515,151 | 0.0% | 0.24% | -28.4% | |
BCTG | BCTG ACQUISITION CORP | $14,225,000 | +2.3% | 1,250,000 | 0.0% | 0.23% | +8.6% | |
ENTX | New | ENTERA BIO LTD | $14,071,000 | – | 2,353,000 | +100.0% | 0.23% | – |
BLSA | BCLS ACQUISITION CORP | $13,163,000 | -0.4% | 1,250,000 | 0.0% | 0.21% | +6.0% | |
CNCE | CONCERT PHARMACEUTICALS INC | $12,802,000 | -15.4% | 3,033,603 | 0.0% | 0.20% | -10.1% | |
New | CATABASIS PHARMACEUTICALS IN | $12,550,000 | – | 5,947,861 | +100.0% | 0.20% | – | |
MIST | MILESTONE PHARMACEUTICALS INC | $12,356,000 | -5.0% | 2,246,503 | 0.0% | 0.20% | +1.0% | |
RACA | New | THERAPEUTICS ACQUISITION COR | $11,284,000 | – | 1,098,318 | +100.0% | 0.18% | – |
EYPT | EYEPOINT PHARMACEUTICALS INC | $11,238,000 | -11.5% | 1,250,000 | 0.0% | 0.18% | -6.2% | |
ARYD | ARYA SCIENCES ACQU CORP IVcl a | $10,720,000 | +2.4% | 1,000,000 | 0.0% | 0.17% | +8.9% | |
OCUL | OCULAR THERAPEUTIX INC | $10,635,000 | -13.6% | 750,000 | 0.0% | 0.17% | -8.1% | |
PHAS | PHASEBIO PHARMACEUTICALS INC | $10,602,000 | +7.5% | 2,850,000 | 0.0% | 0.17% | +14.1% | |
IKNA | IKENA ONCOLOGY INC | $10,530,000 | -50.3% | 750,000 | 0.0% | 0.17% | -47.0% | |
ORIC | ORIC PHARMACEUTICALS INC | $10,331,000 | -27.8% | 584,000 | 0.0% | 0.17% | -23.1% | |
FLACU | FRAZIER LIFESCIENCES ACQUISITION COunit 12/09/2025 | $10,050,000 | -1.1% | 1,000,000 | 0.0% | 0.16% | +5.2% | |
FSII | FS DEVELOPMENT CORP II | $9,980,000 | +0.2% | 1,000,000 | 0.0% | 0.16% | +6.7% | |
TXMD | THERAPEUTICSMD INC | $9,297,000 | -11.2% | 7,812,500 | 0.0% | 0.15% | -5.7% | |
CGEM | CULLINAN ONCOLOGY INC | $9,013,000 | -38.2% | 350,000 | 0.0% | 0.14% | -34.1% | |
COGT | COGENT BIOSCIENCES INC | $8,318,000 | -7.6% | 1,025,641 | 0.0% | 0.13% | -1.5% | |
BMEA | New | BIOMEA FUSION INC | $7,805,000 | – | 500,000 | +100.0% | 0.12% | – |
CVRX | New | CVRX INC | $7,700,000 | – | 275,000 | +100.0% | 0.12% | – |
FVAM | 5 01 ACQUISITION CORP | $7,478,000 | +0.2% | 750,000 | 0.0% | 0.12% | +6.2% | |
HLXA | HELIX ACQUISITION CORP | $7,245,000 | +1.4% | 700,000 | 0.0% | 0.12% | +7.4% | |
HSAQ | HEALTH SCIENCES ACQ CORP 2 | $6,375,000 | -8.9% | 625,000 | 0.0% | 0.10% | -2.9% | |
VRDN | VIRIDIAN THERAPEUTICS INC | $5,712,000 | +9.4% | 312,328 | 0.0% | 0.09% | +16.5% | |
SYRS | SYROS PHARMACEUTICALS INC | $4,905,000 | -27.1% | 900,000 | 0.0% | 0.08% | -22.5% | |
ARPO | New | AERPIO PHARMACEUTICALS INC | $4,552,000 | – | 2,693,309 | +100.0% | 0.07% | – |
CEREW | CEREVEL THERAPEUTICS HLDNG INC*w exp 06/09/2027 | $3,358,000 | +233.8% | 233,333 | 0.0% | 0.05% | +260.0% | |
NTLA | New | INTELLIA THERAPEUTICS INC | $2,429,000 | – | 15,000 | +100.0% | 0.04% | – |
IMRA | IMARA INC | $1,966,000 | -6.4% | 248,804 | 0.0% | 0.03% | 0.0% | |
MCRB | Buy | SERES THERAPEUTICS INC | $1,900,000 | -97.5% | 5,105,547 | +38.2% | 0.03% | -97.4% |
RPHM | New | RENEO PHARMACEUTICALS INC | $580,000 | – | 62,217 | +100.0% | 0.01% | – |
XFOR | Exit | X4 PHARMACEUTICALS INC | $0 | – | -536,962 | -100.0% | -0.07% | – |
RPTX | Exit | REPARE THERAPEUTICS INC | $0 | – | -409,000 | -100.0% | -0.19% | – |
ARYA | Exit | ARYA SCIENCES ACQUISITION CO | $0 | – | -971,430 | -100.0% | -0.20% | – |
PRQR | Exit | PROQR THERAPEUTICS N V | $0 | – | -2,117,669 | -100.0% | -0.21% | – |
SNDX | Exit | SYNDAX PHARMACEUTICALS INC | $0 | – | -1,023,067 | -100.0% | -0.34% | – |
RLAY | Exit | RELAY THERAPEUTICS INC | $0 | – | -1,000,000 | -100.0% | -0.52% | – |
STRO | Exit | SUTRO BIOPHARMA INC | $0 | – | -2,118,212 | -100.0% | -0.73% | – |
CNST | Exit | CONSTELLATION PHARMCETICLS INC | $0 | – | -2,238,536 | -100.0% | -0.79% | – |
IGMS | Exit | IGM BIOSCIENCES INC | $0 | – | -982,723 | -100.0% | -1.14% | – |
ADVM | Exit | ADVERUM BIOTECHNOLOGIES INC | $0 | – | -9,365,833 | -100.0% | -1.39% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
About RA Capital Management
RA Capital Management is a Boston-based investment management firm that specializes in the healthcare sector. The firm was founded in 2001 by Peter Kolchinsky, a former biotech analyst at Lehman Brothers. Since then, RA Capital has grown to become one of the most respected healthcare investment firms in the world, with over $5 billion in assets under management.
The firm's investment strategy is focused on identifying and investing in companies that are developing innovative therapies and technologies that have the potential to transform the healthcare industry. RA Capital's team of experienced analysts and portfolio managers conduct extensive research and due diligence to identify the most promising investment opportunities in the healthcare sector.
RA Capital's portfolio includes a diverse range of companies, from early-stage startups to established biotech and pharmaceutical companies. Some of the notable companies in RA Capital's portfolio include Moderna, a biotech company that is developing a COVID-19 vaccine, and Intellia Therapeutics, a gene editing company that is developing therapies for genetic diseases.
Peter Kolchinsky, the founder and CEO of RA Capital, is a well-respected figure in the healthcare investment community. He is a frequent speaker at industry conferences and has authored several books on biotech investing. Other key members of RA Capital's management team include Rajeev Shah, the firm's COO, and Derek DiRocco, the Chief Investment Officer.
Overall, RA Capital Management is a highly respected investment firm that has a proven track record of identifying and investing in innovative healthcare companies. Investors who are interested in the healthcare sector may want to consider RA Capital as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ASCENDIS PHARMA A/S - ADR | 35 | Q3 2023 | 25.5% |
WAVE LIFE SCIENCES PTE LTD | 32 | Q3 2023 | 26.3% |
TG THERAPEUTICS INC | 30 | Q4 2021 | 6.3% |
ZOGENIX INC | 26 | Q4 2021 | 9.5% |
BIOCRYST PHARMACEUTICALS | 23 | Q1 2019 | 9.2% |
DICERNA PHARMACEUTICALS INC | 23 | Q3 2019 | 5.8% |
RHYTHM PHARMACEUTICALS INC | 22 | Q3 2023 | 4.4% |
ACHILLION PHARMACEUTICALS INC | 19 | Q4 2017 | 17.2% |
KALA PHARMACEUTICALS INC | 19 | Q1 2022 | 4.4% |
SOLID BIOSCIENCES INC | 19 | Q3 2022 | 6.8% |
View RA Capital Management's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
CymaBay Therapeutics, Inc. | September 22, 2023 | 6,940,000 | 6.2% |
BELLUS Health Inc.Sold out | August 14, 2023 | 0 | 0.0% |
Kinnate Biopharma Inc.Sold out | August 14, 2023 | 0 | 0.0% |
Vor Biopharma Inc. | August 11, 2023 | 22,780,343 | 33.7% |
DICE Therapeutics, Inc.Sold out | August 09, 2023 | 0 | 0.0% |
Acumen Pharmaceuticals, Inc. | July 25, 2023 | 14,981,618 | 25.9% |
Talaris Therapeutics, Inc. | July 06, 2023 | 2,333,175 | 5.5% |
Aerovate Therapeutics, Inc. | June 27, 2023 | 8,293,148 | 30.0% |
Satsuma Pharmaceuticals, Inc.Sold out | June 12, 2023 | 0 | 0.0% |
ARYA Sciences Acquisition Corp VSold out | May 15, 2023 | 0 | 0.0% |
View RA Capital Management's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2024-04-15 |
4 | 2024-04-15 |
SC 13G | 2024-04-15 |
SC 13D/A | 2024-04-12 |
SC 13G | 2024-04-12 |
SC 13D/A | 2024-04-11 |
SC 13G | 2024-04-11 |
4 | 2024-04-04 |
SC 13G | 2024-04-04 |
SC 13G | 2024-04-01 |
View RA Capital Management's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.